Isomorphic Labs Raises $5bn Series C in London

London-headquartered AI drug discovery pioneer Isomorphic Labs has raised $5 billion in an oversubscribed Series C funding round. Therefore, marking one of the largest private capital injections in European technology history. Announced during London Life Sciences Week 2026, the round was co-led by Greenoaks and Sequoia Capital. Additionally Andreessen Horowitz (a16z) participated. There was continued backing from parent company Alphabet.

For UK business and commercial leaders, the deal underscores London’s position as a global epicentre for AI-native enterprise growth. Specifically, signalling massive downstream opportunities for specialist suppliers, clinical partners, and B2B service providers.

Scaling AI-Led Bioengineering and Commercial Partnerships

Isomorphic Labs will deploy the capital to advance its foundational simulation models and proprietary drug design engine (IsoDDE). Meanwhile, it will accelerate internal and partnered therapeutic pipelines. Having already secured major commercial partnerships with pharmaceutical giants including Johnson & Johnson, the company is expanding its global bioengineering and clinical development infrastructure.

The announcement lands at a pivotal moment during London Life Sciences Week, where global investors and executives have convened across the capital to evaluate the UK’s commercial innovation ecosystem.

Key Takeaways for Growth Hub Readers

  • Enterprise AI Maturation: High-growth UK tech firms are rapidly transitioning from research-led models to full-scale commercial execution, creating urgent demand for enterprise infrastructure, legal advisory, and technical talent.
  • Ecosystem Spillover for SMEs: Mega-rounds of this scale generate substantial procurement opportunities across specialist lab logistics, cloud infrastructure, regulatory consultancy, and recruitment services.
  • Global Capital Confidence: Backing from top-tier international venture funds demonstrates that UK-headquartered deep-tech businesses can command global scale without relocating headquarters.

Benchmark Your Commercial Strategy for 2027!

As AI-native businesses scale at unprecedented speed, how is your commercial team adapting its go-to-market strategy, sales enablement, and technology stack? Help us build the definitive UK benchmark for commercial growth.

Take part in the 2027 State of Sales Survey!

By contributing your perspective, you will directly shape The Growth Hub’s annual commercial benchmark across UK growth sectors.

Quick & Focused: Takes under five minutes to complete.

Exclusive Access: All contributors receive early access to the full 2027 benchmarking report upon publication.

👉 Click Here to Complete the 2027 State of Sales Survey Now

RECOMMENDED FOR YOU

Tom Elliott – The Magic of Turning Up Your Energy

In part 1 of his Showman-to-Speaker framework, Tom Elliott breaks down the first and arguably most important pillar: persona. Drawing from 15+ years on...

Simon Hazeldine – The 3 account management success drivers

In this Sales Toolkit, Simon Hazeldine provides an overview of the three critical success drivers that form the foundation for effective account management. These...

Myth Busting: Why Sales & Marketing Aren’t Merging

It is often claimed that the functions of sales and marketing are merging but, in reality, this couldn’t be further from the truth. However,...
- Advertisment -

FEATURED

6 CRM Processes to Boost Sales Efficiency

Most salespeople aren’t strangers to processes. Day to day activities typically include lead engagement and then the process of moving each lead through the...